JP2023545183A5 - - Google Patents

Info

Publication number
JP2023545183A5
JP2023545183A5 JP2023522849A JP2023522849A JP2023545183A5 JP 2023545183 A5 JP2023545183 A5 JP 2023545183A5 JP 2023522849 A JP2023522849 A JP 2023522849A JP 2023522849 A JP2023522849 A JP 2023522849A JP 2023545183 A5 JP2023545183 A5 JP 2023545183A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
canine
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023522849A
Other languages
English (en)
Japanese (ja)
Other versions
JP7905331B2 (ja
JP2023545183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/078386 external-priority patent/WO2022079139A1/en
Publication of JP2023545183A publication Critical patent/JP2023545183A/ja
Publication of JP2023545183A5 publication Critical patent/JP2023545183A5/ja
Application granted granted Critical
Publication of JP7905331B2 publication Critical patent/JP7905331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023522849A 2020-10-15 2021-10-14 イヌインターロイキン-31受容体アルファに対するイヌ化抗体 Active JP7905331B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063092296P 2020-10-15 2020-10-15
US202063092294P 2020-10-15 2020-10-15
US63/092,296 2020-10-15
US63/092,294 2020-10-15
US202063127184P 2020-12-18 2020-12-18
US63/127,184 2020-12-18
US202163235258P 2021-08-20 2021-08-20
US202163235257P 2021-08-20 2021-08-20
US63/235,258 2021-08-20
US63/235,257 2021-08-20
PCT/EP2021/078386 WO2022079139A1 (en) 2020-10-15 2021-10-14 Caninized antibodies to canine interleukin-31 receptor alpha

Publications (3)

Publication Number Publication Date
JP2023545183A JP2023545183A (ja) 2023-10-26
JP2023545183A5 true JP2023545183A5 (enExample) 2024-10-17
JP7905331B2 JP7905331B2 (ja) 2026-08-14

Family

ID=78302732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023522849A Active JP7905331B2 (ja) 2020-10-15 2021-10-14 イヌインターロイキン-31受容体アルファに対するイヌ化抗体
JP2023522848A Active JP7902808B2 (ja) 2020-10-15 2021-10-14 イヌインターロイキン-31受容体アルファに対するイヌ化ラット抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023522848A Active JP7902808B2 (ja) 2020-10-15 2021-10-14 イヌインターロイキン-31受容体アルファに対するイヌ化ラット抗体

Country Status (8)

Country Link
US (2) US12577310B2 (enExample)
EP (2) EP4229083A1 (enExample)
JP (2) JP7905331B2 (enExample)
CN (1) CN116348488A (enExample)
AU (2) AU2021359068A1 (enExample)
CA (2) CA3194384A1 (enExample)
MX (2) MX2023004439A (enExample)
WO (2) WO2022079139A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体
JP7905331B2 (ja) * 2020-10-15 2026-08-14 インターベット インターナショナル ベー. フェー. イヌインターロイキン-31受容体アルファに対するイヌ化抗体
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
CN118359715B (zh) * 2023-11-27 2025-08-19 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
CN118063607B (zh) * 2024-03-16 2026-08-07 珠海市丽珠单抗生物技术有限公司 抗犬il-31抗体及其用途
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3954710A3 (en) 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US11091556B2 (en) * 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
CN110563844A (zh) 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
JP7905331B2 (ja) 2020-10-15 2026-08-14 インターベット インターナショナル ベー. フェー. イヌインターロイキン-31受容体アルファに対するイヌ化抗体

Similar Documents

Publication Publication Date Title
JP2023545182A5 (enExample)
JP2022177090A5 (enExample)
JP2021521843A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2024522360A5 (enExample)
JP2022191383A5 (enExample)
JP2024038003A5 (enExample)
JP2021529557A5 (enExample)
JP2022533538A5 (enExample)
JP2022523442A5 (enExample)
JP2023093753A5 (enExample)
JP2023510844A5 (enExample)
JP2012010714A5 (enExample)
JP2021501744A5 (enExample)
JP2012525829A5 (enExample)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2024546763A5 (enExample)
JP2025183307A5 (enExample)
JP2011527899A5 (enExample)
JP2024546759A5 (enExample)
JP2025067915A5 (enExample)
CN110869390A (zh) 抗pd-l1抗体及其用途
RU2012103212A (ru) Tlr3 связывающие агенты
JP2020522280A5 (enExample)